| Income Statement | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net revenues | NaN | NaN | 0 | NaN |
| Research and development expense | 1,519,002 | 1,633,476 | 1,039,713 | 1,958,602 |
| General and administrative expenses | 1,129,447 | 2,447,188 | 1,159,936 | 1,517,415 |
| Total operating expenses | 2,648,449 | 4,080,664 | 2,199,649 | 3,476,017 |
| Loss from operations | -2,648,449 | -4,080,664 | -2,199,649 | -3,476,017 |
| Unrealized loss on crypto assets | NaN | 25,305 | NaN | NaN |
| Realized loss on crypto assets | 44,165 | NaN | NaN | NaN |
| Dividend and interest income | 149 | 168 | 173 | 181 |
| Change in fair value of investment in joint ventures | NaN | NaN | 0 | NaN |
| Total other income (expenses), net | -44,016 | -25,137 | 173 | 181 |
| Net loss | -2,692,465 | -4,105,801 | -2,199,476 | -3,475,836 |
| Foreign currency translation adjustment | 1,578 | -1,016 | 3,478 | -497 |
| Total comprehensive loss | -2,690,887 | -4,106,817 | -2,195,998 | -3,476,333 |
| Basic EPS | -0.17 | -0.3 | -0.17 | -0.27 |
| Diluted EPS | -0.17 | -0.3 | -0.17 | -0.27 |
| Basic Average Shares | 15,792,337 | 13,787,159 | 13,180,243 | 12,727,581 |
| Diluted Average Shares | 15,792,337 | 13,787,159 | 13,180,243 | 12,727,581 |
Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. (HOTH)